Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432346 | 0.87 | — | — | |
| SCHEMBL4434738 | 0.85 | — | — | |
| SCHEMBL4429352 | 0.83 | — | — | |
| SCHEMBL4435132 | 0.83 | — | — | |
| SCHEMBL4425759 | 0.82 | POLB (0.51) | — | |
| SCHEMBL4427951 | 0.79 | — | — | |
| SCHEMBL10928799 | 0.75 | ACP3 (0.66) | ACP3 | |
| SCHEMBL5035396 | 0.74 | ACP3 (0.64) | ACP3 | |
| SCHEMBL11349187 | 0.73 | ACP3 (0.68) | ACP3 | |
| SCHEMBL1246417 | 0.72 | ACP3 (0.62) | ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-7638505-B2 | Organophosphoric derivatives useful as anti-parasitic agents | UNIVERSITEIT GENT (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | UNIVERSITEIT GENT (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | ACP3 4134/4885 |
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | SUB1, CBR1, NAT1 | ACP3 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.